Analytical Data
-
基因名
APOA1
- Application
-
别名
Apo-A1; ApoA-1 Milano; ProapoA-I; Proapolipoprotein A-I; Truncated apolipoprotein A-I
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P02647
-
表达区间
Gln122~Gln267
-
分子量
17kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Apolipoprotein A-I (APOA1) is a key protein component of high-density lipoproteins (HDL) and plays a crucial role in lipid metabolism and cardiovascular health. It is primarily synthesized in the liver and intestines and is essential for the formation and stabilization of HDL particles, which are responsible for the reverse transport of cholesterol from peripheral tissues to the liver for excretion. Research has shown that APOA1 is involved in various physiological processes, including anti-inflammatory and antioxidant activities, as well as modulation of cholesterol efflux and cellular lipid homeostasis. Given its significant role in cardiovascular disease, low levels of APOA1 are associated with an increased risk of atherosclerosis and heart disease. As a result, recombinant APOA1 has emerged as a potential therapeutic agent for cardiovascular diseases. Studies have focused on the production of recombinant APOA1 to evaluate its effects on lipid metabolism, cholesterol transport, and the overall lipid profile in animal models and human clinical trials. The development of APOA1-based therapies aims to enhance HDL functionality, improve lipid profiles, and ultimately reduce cardiovascular risk, making it an essential target for ongoing research in the field of cardiovascular medicine and metabolic disorders.
